CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma
<p>Abstract</p> <p>Classical Hodgkin lymphoma (CHL) is a B-cell lymphoproliferative disorder with a relatively good prognosis. A small but significant percentage of patients, however, will respond poorly to therapy. A recent gene expression profiling study has identified a macropha...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-01-01
|
| Series: | Diagnostic Pathology |
| Online Access: | http://www.diagnosticpathology.org/content/7/1/12 |
| _version_ | 1818395086960984064 |
|---|---|
| author | Harris Jonathan A Jain Salvia Ren Qinghu Zarineh Alirezah Liu Cynthia Ibrahim Sherif |
| author_facet | Harris Jonathan A Jain Salvia Ren Qinghu Zarineh Alirezah Liu Cynthia Ibrahim Sherif |
| author_sort | Harris Jonathan A |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Classical Hodgkin lymphoma (CHL) is a B-cell lymphoproliferative disorder with a relatively good prognosis. A small but significant percentage of patients, however, will respond poorly to therapy. A recent gene expression profiling study has identified a macrophage signature which has been correlated with primary treatment failure, and immunohistochemical tissue microarray for CD68 was shown to reflect the gene signature as a potentially clinically useful marker to predict adverse prognosis.</p> <p>We examined 44 cases of CHL, mostly nodular sclerosis subtype, in which the immunohistochemical stains for the histiocytic markers CD68 and CD163 were performed. The staining intensity was graded for each stain (< 5, 5-25, and > 25 percent of cells positive in the Hodgkin cell (HC) rich nodules) and background staining characteristics were recorded.</p> <p>CD163 staining was lower than CD68 in HC rich nodules, with lower background staining (p 0.03). There was no significant difference between either CD68 or CD163 and disease recurrence in a subset (N = 41) of cases.</p> <p>In conclusion, we demonstrate that CD163 staining is lower than CD68, with less non-specific staining of background inflammatory cells and Hodgkin cells, therefore is a better marker for tumor associated macrophages. However, we did not identify a correlation between staining for CD68 or CD163 and recurrence of disease.</p> <p>Virtual slides</p> <p>The virtual slide(s) for this article can be found here:</p> <p><url>http://www.diagnosticpathology.diagnomx.eu/vs/1460518258831620</url></p> |
| first_indexed | 2024-12-14T06:11:31Z |
| format | Article |
| id | doaj.art-d3251c72d8cb44edaea0244bfc659a9e |
| institution | Directory Open Access Journal |
| issn | 1746-1596 |
| language | English |
| last_indexed | 2024-12-14T06:11:31Z |
| publishDate | 2012-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Diagnostic Pathology |
| spelling | doaj.art-d3251c72d8cb44edaea0244bfc659a9e2022-12-21T23:14:09ZengBMCDiagnostic Pathology1746-15962012-01-01711210.1186/1746-1596-7-12CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphomaHarris Jonathan AJain SalviaRen QinghuZarineh AlirezahLiu CynthiaIbrahim Sherif<p>Abstract</p> <p>Classical Hodgkin lymphoma (CHL) is a B-cell lymphoproliferative disorder with a relatively good prognosis. A small but significant percentage of patients, however, will respond poorly to therapy. A recent gene expression profiling study has identified a macrophage signature which has been correlated with primary treatment failure, and immunohistochemical tissue microarray for CD68 was shown to reflect the gene signature as a potentially clinically useful marker to predict adverse prognosis.</p> <p>We examined 44 cases of CHL, mostly nodular sclerosis subtype, in which the immunohistochemical stains for the histiocytic markers CD68 and CD163 were performed. The staining intensity was graded for each stain (< 5, 5-25, and > 25 percent of cells positive in the Hodgkin cell (HC) rich nodules) and background staining characteristics were recorded.</p> <p>CD163 staining was lower than CD68 in HC rich nodules, with lower background staining (p 0.03). There was no significant difference between either CD68 or CD163 and disease recurrence in a subset (N = 41) of cases.</p> <p>In conclusion, we demonstrate that CD163 staining is lower than CD68, with less non-specific staining of background inflammatory cells and Hodgkin cells, therefore is a better marker for tumor associated macrophages. However, we did not identify a correlation between staining for CD68 or CD163 and recurrence of disease.</p> <p>Virtual slides</p> <p>The virtual slide(s) for this article can be found here:</p> <p><url>http://www.diagnosticpathology.diagnomx.eu/vs/1460518258831620</url></p>http://www.diagnosticpathology.org/content/7/1/12 |
| spellingShingle | Harris Jonathan A Jain Salvia Ren Qinghu Zarineh Alirezah Liu Cynthia Ibrahim Sherif CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma Diagnostic Pathology |
| title | CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma |
| title_full | CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma |
| title_fullStr | CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma |
| title_full_unstemmed | CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma |
| title_short | CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma |
| title_sort | cd163 versus cd68 in tumor associated macrophages of classical hodgkin lymphoma |
| url | http://www.diagnosticpathology.org/content/7/1/12 |
| work_keys_str_mv | AT harrisjonathana cd163versuscd68intumorassociatedmacrophagesofclassicalhodgkinlymphoma AT jainsalvia cd163versuscd68intumorassociatedmacrophagesofclassicalhodgkinlymphoma AT renqinghu cd163versuscd68intumorassociatedmacrophagesofclassicalhodgkinlymphoma AT zarinehalirezah cd163versuscd68intumorassociatedmacrophagesofclassicalhodgkinlymphoma AT liucynthia cd163versuscd68intumorassociatedmacrophagesofclassicalhodgkinlymphoma AT ibrahimsherif cd163versuscd68intumorassociatedmacrophagesofclassicalhodgkinlymphoma |